Snoretox
Emerging biotech company developing modified tetanus-toxin-derived muscle-toning biologics for human and veterinary use. Program focus includes treatments for low-muscle-tone conditions (e.g., brachycephalic obstructive airway syndrome in dogs, sleep apnoea/snoring, sphincter weakness and other muscle weakness disorders). Research and discovery were undertaken in collaboration with RMIT University; activities include preclinical research, veterinary clinical studies, regulatory engagement, grant-funded development and early-stage commercialization efforts.
Industries
Nr. of Employees
small (1-50)
Products
Modified tetanus toxin-derived muscle-toning biologic (human and veterinary)
Biologic therapeutic based on engineered tetanus-toxin molecules intended to increase muscle tone when administered in minute amounts via targeted intramuscular injection; proposed indications include sleep apnoea/snoring, brachycephalic obstructive airway syndrome (BOAS) in dogs, sphincter weakness and other low-tone muscle conditions.
Modified tetanus toxin-derived muscle-toning biologic (human and veterinary)
Biologic therapeutic based on engineered tetanus-toxin molecules intended to increase muscle tone when administered in minute amounts via targeted intramuscular injection; proposed indications include sleep apnoea/snoring, brachycephalic obstructive airway syndrome (BOAS) in dogs, sphincter weakness and other low-tone muscle conditions.
Services
Recruitment and coordination of veterinary patients (canine) for investigational therapeutic studies, including on-site administration and monitoring.
Engagement with academic institutions and commercial consultants to progress discovery-stage biologics toward development and market entry.
Recruitment and coordination of veterinary patients (canine) for investigational therapeutic studies, including on-site administration and monitoring.
Engagement with academic institutions and commercial consultants to progress discovery-stage biologics toward development and market entry.
Expertise Areas
- Muscle-toning biologic development
- Veterinary therapeutic development (canine BOAS and related conditions)
- Preclinical translational research
- Regulatory strategy for veterinary biologics
Key Technologies
- Modified protein-toxin biologics
- Intramuscular delivery techniques
- Preclinical animal models (canine studies)
- Molecular immunology assays
News & Updates
Selected as the winner in the Emerging Companies Competition at the Animal Health Summit; unanimous judge selection and recognition at an industry deal-making event for veterinary pharmaceutical companies.
Selected to participate in the Emerging Company Presentations at the KC Animal Health Summit (August 2025).
Media coverage describing a trial participant pug that received investigational injections with reported respiratory and behavioral improvement.
First scientific publication related to the program published in Molecular Immunology (November 2020).
Awarded a Medical Research Future Fund (MRFF) Frontier Health and Medical Research Initiative grant (A$1 million) to support translation toward the clinic.
Awarded a commercialization grant from the Medical Technology Enterprise Consortium (MTEC) to develop a neurotoxin-based therapeutic for muscle injury.
Selected as the winner in the Emerging Companies Competition at the Animal Health Summit; unanimous judge selection and recognition at an industry deal-making event for veterinary pharmaceutical companies.
Selected to participate in the Emerging Company Presentations at the KC Animal Health Summit (August 2025).
Media coverage describing a trial participant pug that received investigational injections with reported respiratory and behavioral improvement.
First scientific publication related to the program published in Molecular Immunology (November 2020).
Awarded a Medical Research Future Fund (MRFF) Frontier Health and Medical Research Initiative grant (A$1 million) to support translation toward the clinic.
Awarded a commercialization grant from the Medical Technology Enterprise Consortium (MTEC) to develop a neurotoxin-based therapeutic for muscle injury.